The Rise of the Retail Market of 20 Billion Cardiovascular Chemicals

Wonderful content

According to data from Mi Nei, in 2020, the market sales of terminal cardiovascular system drugs in physical pharmacies in cities in China will exceed 20 billion yuan.
From the perspective of dosage forms, oral-related dosage forms account for nearly 98% of the market
.

The 20 billion market hits a new high, Hisun Class 1 new drugs, Hengrui, Hisco.
.
.
the first imitations are coming

A few days ago, Haisco issued an announcement saying that its wholly-owned sun company Haisco Pharmaceuticals (Meishan) was approved for imitation of perindopril indapamide tablets for production in Category 4, becoming the first imitation + first review of the product.
"Enterprise
.

Sales of Perindopril and Indapamide Tablets in Chinese Urban Entity Pharmacies in Recent Years (Unit: Ten Thousand Yuan)

Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

Perindopril indapamide tablets were developed by French LES LABORATOIRES SERVIER, and were first marketed in France in 1997.
The original manufacturer LES LABORATOIRES SERVIER's perindopril indapamide tablets were approved in 2005 by Servier (Tianjin) Pharmaceutical production
.

Sales of terminal cardiovascular system chemicals in physical pharmacies in cities in China in recent years (unit: 100 million yuan)

Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

With the intensification of the aging of the population, under the influence of factors such as life and diet, the scale of the retail market for cardiovascular diseases and other related drugs has gradually expanded
.

From the perspective of TOP10 manufacturers, Pfizer, AstraZeneca, Novartis and other foreign-funded pharmaceutical companies occupy 7 seats.
The domestic pharmaceutical companies are only Shihuida Pharmaceutical Group (Jilin), CSPC Enbipu Pharmaceutical and Lunanbeite Pharmaceutical.

.

Oral cardiovascular system chemicals approved for marketing since 2021

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

Since the beginning of this year, a total of 30 oral cardiovascular drugs have been approved for marketing, among them, Hesco Pharmaceuticals (Meishan)'s perindopril indapamide tablets, Jiangsu Hengrui Medicine's Azilsartan tablets, and Beijing Jialin Pharmaceutical Amlodipine Atorvastatin Calcium Tablets, Hunan Jiudian Pharmaceutical’s Imidapril Hydrochloride Tablets, Sichuan Pride Times Pharmaceutical’s Telmisartan and Amlodipine Tablets (Ⅱ), Henan Bainian Kangxin Pharmaceutical’s Hydrochloric Acid Nalolol oral liquid, ivabradine hydrochloride tablets from Beijing Biopharmaceuticals, and omega-3-acid ethyl ester 90 soft capsules from Sichuan Guowei Pharmaceutical are the first imitations
.

In addition, Zhejiang Hisun Pharmaceutical's Class 1 new drug Haibo Maibu Tablets (formerly known as Haize Maibu Tablets) was approved at the end of June.
This product is used as an adjuvant treatment other than diet control and can be used alone or with HMG-CoA.
Reductase inhibitors (statins) are used in combination to treat primary (heterozygous familial or non-familial) hypercholesterolemia, which can reduce total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), load Lipoprotein B (Apo B) levels
.

TOP20 products are out! Two major products over 2 billion "leader", this one skyrocketed by 80%

2020 China's urban physical pharmacies terminal cardiovascular system chemical products TOP20 (unit: 100 million yuan)

Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

Note: Sales of less than 500 million yuan are displayed with "*"

The total market share of TOP20 products accounts for more than 70%, and the market concentration is relatively high.
The product formulations are mainly tablets
.

Sales of Atorvastatin Calcium Tablets in Chinese Urban Entity Pharmacies in Recent Years (Unit: 100 million yuan)

Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

According to data from Meinenet, in recent years, the sales of atorvastatin calcium tablets in physical pharmacies in Chinese cities have exceeded 2 billion yuan.
Among them, Pfizer has the largest market share, exceeding 75%; Lepu Pharmaceutical and Beijing Jialin Pharmaceutical rank second.
Three
.

Sales of Amlodipine Besylate Tablets in Chinese Urban Entity Pharmacies in Recent Years (Unit: 100 million yuan)

Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

According to data from Meinnet.
com, the sales of amlodipine besylate tablets in physical pharmacies in Chinese cities have grown steadily in recent years.
In 2019, it exceeded 2 billion yuan for the first time and reached a new high in 2020, an increase of 6.
74% year-on-year
.

In terms of growth rate, sacubitril and valsartan sodium tablets are the fastest, with a growth rate of more than 80%, becoming the TOP20 product; in addition, valsartan and amlodipine tablets (Ⅰ), metoprolol succinate tablets The growth rate of release tablets, bisoprolol fumarate tablets, and nifedipine controlled release tablets all exceeded 10%
.

30 products swarmed! Three major products of pharmaceutical companies "getting together"

Oral cardiovascular drugs reported for production and under review from 2021 to present

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

Since the beginning of this year, a total of 30 oral cardiovascular chemicals have submitted marketing applications for review and approval
.

Eicosapentaenoic acid ethyl ester soft capsules, enalapril maleate oral solution, nimodipine oral solution, sacubitril and valsartan sodium tablets, clonidine hydrochloride sustained-release tablets, ezetimibutol Seven products including Vastatin calcium tablets have not been approved for generic drugs.